Each individually sealed vial contains 10 mg of DSIP at 99% purity by HPLC
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
A medical professional should supervise dosage adjustments
Logarithmic growth phase cells were inoculated in 6-well plates at a density of 350,000/well and transfected after 24 h
It measures how much of the material is the target peptide versus impurities
BPC-157 supports the healing of muscles, tendons, ligaments, and even the gut lining